FOLD - Company ID 0001178879
The table below shows AMICUS THERAPEUTICS, INC.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $634.21M | $528.29M | $399.36M | $329.23M | $305.51M | $260.89M |
| Cost of revenue | $72.93M | $52.94M | $37.33M | $38.60M | $34.47M | $31.04M |
| Gross profit | $561.28M | $475.35M | $362.03M | $290.63M | $271.05M | $229.84M |
| R&D | - | - | - | - | - | - |
AMICUS THERAPEUTICS, INC. reported annual revenue of $634.21M for fiscal year 2025. That is up 20.0% from $528.29M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $4.96M (FY 2016) to $634.21M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $383.49M |
| $323.38M |
| $275.27M |
| $213.04M |
| $192.71M |
| $156.41M |
| Operating income | $32.79M | $24.88M | -$77.21M | -$212.12M | -$206.43M | -$247.00M |
| Income tax | $27.30M | $27.35M | $1.48M | -$5.47M | $8.91M | $2.60M |
| Net income | -$27.11M | -$56.11M | -$151.58M | -$236.57M | -$250.46M | -$276.85M |
| EPS (diluted) | -$0.09 | -$0.18 | -$0.51 | -$0.82 | -$0.92 | -$1.07 |